Priority Review Voucher sale proceeds received
Released
Released
Announcement PDF
Neuren (NEU) – ASX Announcement
7 February 2025
Priority Review Voucher sale proceeds received
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) announced that it has today received in cash
its one-third share of the net proceeds from the sale of the Rare Pediatric Disease Priority Review
Voucher (PRV). Neuren’s partner Acadia Pharmaceuticals (NASDAQ: ACAD) successfully completed the
sale of the PRV for US$150m on 11 December 2024.
The PRV was granted to Acadia by the U.S. Food and Drug Administration (FDA) following the approval of
DAYBUETM (trofinetide) for the treatment of Rett syndrome. Under the license agreement between
Neuren and Acadia, Neuren receives one-third of the proceeds, net of any applicable costs.
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options. Recognising the urgent unmet
need, all programs have been granted “orphan drug” designation in the United States. Orphan drug
designation provides incentives to encourage development of therapies for rare and serious diseases.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for
the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia
Pharmaceuticals Inc. for the development and commercialisation of trofinetide.
Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental
disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt
Hopkins syndrome and Angelman syndrome.
Contact:
investorrelations@neurenpharma.com
Jon Pilcher, CEO: +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the CEO of Neuren Pharmaceuticals
Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
1 of 1
Share your feedback
Discover